Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis (2019)
- Authors:
- USP affiliated authors: BONATO, PIERINA SUELI - FCFRP ; LANCHOTE, VERA LUCIA - FCFRP ; TAKAYANAGUI, OSVALDO MASSAITI - FMRP
- Unidades: FCFRP; FMRP
- DOI: 10.1093/cid/ciz085
- Subjects: NEUROCISTICERCOSE; ANTIPARASITÁRIOS; ANTI-HELMÍNTICOS; CISTOS
- Keywords: Albendazole; Albendazole sulfoxide; Praziquantel; Neurocysticercosis
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical Infectious Diseases
- ISSN: 1058-4838
- Volume/Número/Paginação/Ano: v. 69, n. 11, p. 1996-2002, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ARROYO, Gianfranco et al. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clinical Infectious Diseases, v. 69, n. 11, p. 1996-2002, 2019Tradução . . Disponível em: https://doi.org/10.1093/cid/ciz085. Acesso em: 13 fev. 2026. -
APA
Arroyo, G., Bustos, J. A., Lescano, A. G., Gonzales, I., Saavedra, H., Rodriguez, S., et al. (2019). Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clinical Infectious Diseases, 69( 11), 1996-2002. doi:10.1093/cid/ciz085 -
NLM
Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis [Internet]. Clinical Infectious Diseases. 2019 ; 69( 11): 1996-2002.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1093/cid/ciz085 -
Vancouver
Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis [Internet]. Clinical Infectious Diseases. 2019 ; 69( 11): 1996-2002.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1093/cid/ciz085 - Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis
- Medical management of neurocysticercosis
- Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma
- Simultaneous determination of albendazole metabolites, praziquantel and its metabolite in plasma by high-performance liquid chromatography-electrospray mass spectrometry
- Silmutaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma
- Análise do albendazol sulfóxido e albendazol sulfona em plasma empregando LC-MS/MS
- Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis
- Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: application to pharmacokinetics
- Therapy for neurocysticercosis: pharmacokinetic interactions of (+)-albendazole sulfoxide with cimetidine and ranitidine
- Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis
Informações sobre o DOI: 10.1093/cid/ciz085 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
002978353.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
